Improving Safety of Direct Oral Anticoagulant (DOAC) Dosing in Patients with Severe Chronic and End-Stage Renal Disease

Presenter Information

Naman Upadhyay, MD, Thomas Jefferson UniversityFollow
R. Mohammed, MD, Thomas Jefferson UniversityFollow
Kirpal Kochar, MD, Thomas Jefferson UniversityFollow
Max Ruge, MD, Thomas Jefferson UniversityFollow
Sean Dikdan, MD, Thomas Jefferson UniversityFollow
Yair Lev, MD, Thomas Jefferson UniversityFollow

Start Date

5-27-2021 9:00 AM

End Date

5-27-2021 5:00 PM

Description

The significance of this study is to determine the degree of inconsistency in dosing practice of DOACs at a quaternary care institution such as Thomas Jefferson University Hospital.

1. What is the primary indication for anticoagulation in out population?
2. What percentage is dosed correctly?
3. Are patients primarily over or underdosed?

Keywords

DOACs, End stage renal disease, advanced CKD, apixaban, rivaroxaban

Comments

Presented at the 2021 House Staff Quality Improvement and Patient Safety Conference